Showing 821-830 of 1350 results for "".
- Benign Nail Condition Linked to Cancer Riskhttps://practicaldermatology.com/news/benign-nail-condition-linked-cancer-risk/2463171/The presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (eg, the mesothelium), according to scientists at the National Institu
- Antihypertensive Drugs Linked to Increased Eczema in Elderlyhttps://practicaldermatology.com/news/antihypertensive-drugs-linked-increased-eczema-elderly/2463140/New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. Researchers conducted a longitudinal cohort study in a population-based sample from primary care practices in The Health Improvement Network in the United Kingd
- Research IDs New Psoriasis Inflammation Pathwayhttps://practicaldermatology.com/news/research-ids-new-psoriasis-inflammation-pathway/2463125/Researchers from a recent study have identified a key biological pathway responsible for the inflammation seen in psoriasis, with potential implications for other inflammatory diseases like atopic dermatitis, allergic dermatitis, and hidradenitis suppurativa. The study, published in the j
- Analysis: Scar Reduction Seen with Fractional CO2 and 5-FU Laser Treatmentshttps://practicaldermatology.com/news/analysis-scar-reduction-seen-fractional-co2-and-5-fu-laser-treatments/2463110/Results from a new meta-analysis suggest that fractional carbon dioxide (FCO2) plus 5-fluorouracil (5-FU) laser therapy was effective in treating hypertrophic and keloid scars. Researchers for the analysis included data from 18 studies (N = 550). The team comprehensively search
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Pilot Study Supports Once-Daily Isotretinoin for Acne Treatmenthttps://practicaldermatology.com/news/pilot-study-supports-once-daily-isotretinoin-acne-treatment/2463088/Micronized isotretinoin administered once per day without food was effective and well-tolerated for the treatment of severe nodular acne, new study results indicate. Researchers for the pilot study focused on and evaluated a regimen of once-daily micronized isotretinoin (0.4 to 0.8 mg/kg/
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://practicaldermatology.com/news/dr-jeanine-downie-discusses-fake-botox-tv-segment/2463070/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie, an Editorial Board member for Practical Dermatology's sister publication Mode
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- Impact of Alopecia Areata on Pediatric Patients and Their Families: Insights from a Single-Center Study in Turkeyhttps://practicaldermatology.com/news/impact-alopecia-areata-pediatric-patients-and-their-families-insights-single-center-study-turkey/2462829/Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. To address this gap, researchers recently conducted a single-center cross-s